BLUE:NSD-bluebird bio, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 48.10

Change

+1.46 (+3.13)%

Market Cap

USD 3.10B

Volume

1.56M

Average Target Price

USD 78.53 (+63.26%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of ß-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases, as well as clinical trial collaboration with Magenta Therapeutics. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts. Address: 60 Binney Street, Cambridge, MA, United States, 02142

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.72 (+1.57%)

USD61.78B 23.28 18.31
REGN Regeneron Pharmaceuticals, Inc

+10.42 (+1.94%)

USD57.38B 19.71 15.20
MRNA Moderna, Inc

+15.98 (+12.20%)

USD51.85B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.59 (+1.00%)

USD34.94B 37.07 34.58
BGNE BeiGene, Ltd

+2.41 (+0.64%)

USD34.10B N/A N/A
SGEN Seagen Inc

-2.63 (-1.44%)

USD32.71B 69.01 69.56
RPRX Royalty Pharma plc

+0.34 (+0.66%)

USD31.99B 22.60 11.74
GMAB Genmab A/S

-0.36 (-0.84%)

USD28.33B 26.59 3.19
BNTX BioNTech SE

+2.17 (+2.00%)

USD26.11B -99,999.99 N/A
INCY Incyte Corporation

+2.61 (+2.67%)

USD21.44B 47.64 35.20

ETFs Containing BLUE

Symbol Name Weight Mer Price(Change) Market Cap
LABD Direxion Daily S&P Biotec.. 0.00 % 1.06 %

-1.70 (-8.83%)

USD0.16B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.16% 40% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.16% 40% F 63% D
Trailing 12 Months  
Capital Gain -42.13% 11% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.13% 11% F 5% F
Trailing 5 Years  
Capital Gain 13.10% 49% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.10% 49% F 28% F
Average Annual (5 Year Horizon)  
Capital Gain 24.66% 64% D 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.66% 64% D 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 78.48% 31% F 14% F
Risk Adjusted Return 31.43% 61% D- 56% F
Market Capitalization 3.10B 86% B 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.03 85% B 62% D-
Price / Cash Flow Ratio -5.49 37% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -42.89% 68% D+ 25% F
Return on Invested Capital -49.00% 60% D- 19% F
Return on Assets -21.29% 63% D 18% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.36 27% F 18% F
Short Percent 15.81% 14% F 12% F
Beta 1.88 31% F 19% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector